肾移植术后巨细胞病毒感染的研究进展

肖培; 徐正红; 芦幸; 杨红枚

肾移植术后巨细胞病毒感染的研究进展

- 华中科技大学同济医学院基础医学院病原生物学系(武汉, 430030)
基金项目:
国家自然科学基金面上项目（编号3100142）

详细信息

通讯作者: 杨红枚,E-mail:macy.yang88@gmail.com

中图分类号: R692

收稿日期: 2012-07-30

Corresponding author: , E-mail: macy.yang88@gmail.com

Received Date: 30 July 2012

摘要

摘要: 潜伏的巨细胞病毒（cytomegalovirus，CMV）活化或新的CMV感染，多发生在肾移植术后的第二和第四个月之间，是移植术后的常见并发症之一，从而对机体造成直接或间接的影响。本文针对肾移植术后CMV感染和CMV病的危险因素、临床表现、诊断以及防治方面做一简要综述。
- 肾移植 /
- 巨细胞病毒感染

HTML全文

参考文献(35)

[1]	LJUNGMAN P,GRIFFITHS P,PAYA C. Definitions of cytomegalovirus infection and disease in transplant recipients[J]. Clin Infect Dis,2002,34:1094-1097.
[2]	KOTTON C N,KUMAR D,CALIENDO A M,et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation[J]. Transplantation,2010,89:779-795.
[3]	FISHMAN J A,EMERY V,FREEMAN R,et al. Cytomegalovirus in transplantation-challenging the status quo[J]. Clin Transplant,2007,21:149-158.
[4]	WEIKERT B C,BLUMBERG E A. Viral infection after renal transplantation:surveillance and management[J]. Clin J Am Soc Nephrol,2008,3 Suppl 2:S76-86.
[5]	CORDERO E,CASASOLA C,ECARMA R,et al. Cytomegalovirus disease in kidney transplant recipients:incidence,clinical profile,and risk factors[J]. Transplant Proc,2012,44:694-700.
[6]	唐斌,吕培燕,许风英,等. 肾移植术后巨细胞病毒感染对受者远期肾功能的影响[J]. 南方医科大学学报,2009,29(8):1588-1591.
[7]	AOBOTT K C,HYPOLITE I O,VIOLA R,et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States[J]. Ann Epidemiol,2002,12:402-409.
[8]	DE KEYZER K,VAN LAECKE S,PEETERS P,et al. Human cytomegalovirus and kidney transplantation:a clinician's update[J]. Am J Kidney Dis,2011,58:118-126.
[9]	REISCHIG T. Cytomegalovirus-associated renal allograft rejection:new challenges for antiviral preventive strategies[J]. Expert Rev Anti Infect Ther,2010,8:903-910.
[10]	TOLKOFF-RUBIN N E, FISHMAN J A, RUBIN R H. The bidirectional relationship between cytomegalovirus and allograft injury[J]. Transplant Proc, 2001, 33:1773-1775.
[11]	ARTHURS S K, EID A J, PEDERSEN R A, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation[J]. Clin Infect Dis, 2008, 46:840-846.
[12]	KUTE V B, VANIKAR A V, SHAH P R, et al. Post-renal transplant cytomegalovirus infection:study of risk factors[J]. Transplant Proc, 2012, 44:706-709.
[13]	FAURE-DELLA CORTE M, SAMOT J, GARRIGUE I, et al. Variability and recombination of clinical human cytomegalovirus strains from transplantation recipients[J]. J Clin Virol, 2010, 47:161-169.
[14]	HODSON E M, JONES C A, WEBSTER A C, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants:a systematic review of randomised controlled trials[J]. Lancet, 2005, 365:2105-2015.
[15]	MARCHETTI S, SANTANGELO R, MANZARA S, et al. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants[J]. New Microbiol, 2011, 34:157-164.
[16]	PIIPARINEN H, HELANTERÄ I, LAPPALAINEN M, et al. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients[J]. J Med Virol, 2005, 76:367-372.
[17]	LIU J B, ZHANG Z. Development of SYBR Green I-based real-time PCR assay for detection of drug resistance mutations in cytomegalovirus[J]. J Virol Methods, 2008, 149:129-135.
[18]	WATTAL C, JOSHI S, GUPTA A, et al. The pp67 mRNA assay in treatment and monitoring of cytomegalovirus disease in renal transplant patients in India[J]. Transpl Infect Dis, 2004, 6:90-92.
[19]	LEE S, PARK J B, KIM E Y, et al. Monitoring of cytomegalovirus-specific CD8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients[J]. Transplant Proc, 2011, 43:2636-2640.
[20]	KOTTON C N. Management of cytomegalovirus infection in solid organ transplantation[J]. Nat Rev Nephrol, 2010, 6:711-721.
[21]	MERCORELLI B, LEMBO D, PALÙ G, et al. Early inhibitors of human cytomegalovirus:state-of-art and therapeutic perspectives[J]. Pharmacol Ther, 2011, 131:309-329.
[22]	高陈, 彭龙开. 肾移植术后巨细胞病毒感染的诊断和防治进展[J]. 复旦学报(医学版), 2011, 38(2):172-176.
[23]	HUMAR A, SNYDMAN D. Cytomegalovirus in solid organ transplant recipients[J]. Am J Transplant, 2009, 9 Suppl 4:S78-86.
[24]	HUMAR A, LEBRANCHU Y, VINCENTI F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients[J]. Am J Transplant, 2010, 10:1228-1237.
[25]	HELANTERÄ I, KYLLÖNEN L, LAUTENSCHLAGER I, et al. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis[J]. Am J Transplant, 2010, 10:2026-2032.
[26]	WITZKE O, HAUSER I A, BARTELS M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients:1-year results of a randomized clinical trial[J]. Transplantation, 2012, 93:61-68.
[27]	VAN DER BEEK M T, BERGER S P, VOSSEN A C, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation:comparison of treatment failure and antiviral resistance[J]. Transplantation, 2010, 89:320-326.
[28]	MONTEJO M, PORTO M, CARMON O, et al. Prophylactic therapy with valganciclovir in high-risk(cytomegalovirus D+/R-)kidney transplant recipients:a single-center experience[J]. Transplant Proc, 2010, 42:2947-2949.
[29]	EID A J, RAZONABLE R R. New developments in the management of cytomegalovirus infection after solid organ transplantation[J]. Drugs, 2010, 70:965-981.
[30]	RAZONABLE R R. Immune-based therapies for cytomegalovirus infection[J]. Immunotherapy, 2010, 2:117-130.
[31]	PASS R F, ZHANG C, EVANS A, et al. Vaccine prevention of maternal cytomegalovirus infection[J]. N Engl J Med, 2009, 360:1191-1199.
[32]	SCHLEISS M R. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection[J]. Curr Opin Mol Ther, 2009, 11:572-578.
[33]	ZHONG J, RIST M, COOPER L, et al. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus[J]. PLoS One, 2008, 3:e3256.
[34]	LANIER R, TROST L, TIPPIN T, et al. Development of CMX001 for the Treatment of Poxvirus Infections[J]. Viruses, 2010, 2:2740-2762.
[35]	KAUL D R, STOELBEN S, COBER E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246[J]. Am J Transplant, 2011, 11:1079-1084.